Twist Bioscience Corporation announced on October 31, 2024, a collaboration with Absci Corporation to design a novel therapeutic antibody using generative AI. This partnership combines Absci's data-first generative AI drug creation platform with Twist's DNA synthesis platform.
The collaboration aims to accelerate the design of new therapeutic antibodies, leveraging advanced technology in drug discovery. This initiative positions Twist at the forefront of AI-driven biological engineering, enhancing its capabilities in the biopharma market.
By integrating AI into its antibody design workflows, Twist seeks to streamline the discovery process and potentially bring new therapeutic candidates to market more efficiently. This strategic alliance expands Twist's reach and application in the rapidly evolving field of drug development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.